In most institutions, planning computed tomography (CT) scans are not interpreted by diagnostic radiologists. The purpose of this analysis was to determine the percentage of cases in which a previously undetected radiographic finding was found on review of CT simulation images by diagnostic radiology. Methods: At the Henry Ford West Bloomfield Center, CT simulations are prospectively interpreted by diagnostic radiologists and a formal report is generated. CT simulation scan reports of 332 consecutive breast cancer patients from 2000 to 2006 were reviewed. The percentage of these reports in which a previously undetected abnormality was noted on the planning CT was determined. Prior and subsequent diagnostic CT scans were also reviewed to determine the clinical relevance of these diagnostic abnormalities. Results: Of 332 patients with CT simulations for breast cancer treatment planning, 52 patients (16%) had a newly detected abnormality noted. Of these, 31 patients (or 60% of the abnormal findings) were deemed by diagnostic radiology to have potentially significant findings (eg, "can not exclude metastatic disease"), and a follow-up CT or magnetic resonance imaging scan was recommended. Abnormalities in this category included previously undetected lung nodules, liver lesions, kidney/adrenal lesions, and sclerotic bony lesions. On follow-up, however, to date, these findings have demonstrated no clinical significance, although further follow-up is needed in many patients.
C omputed tomography (CT) based treatment planning before radiotherapy for breast and many other cancers has become the standard of care in radiation oncology departments. CT simulation allows for the 3D visualization of the area of interest before the actual administration of radiation therapy. Planning technologies yield precise localization of the treatment volume to minimize radiation exposure to normal critical organs, which in the case of breast cancer, includes the lung and heart. CT treatment planning can also be used to plan the breast boost volume. 1 Studies have shown that radiotherapy fields designed with the aid of CT planning scans result in better tumor targeting and normal tissue dose distributions over a range of cancer sites. 2, 3 In most institutions, CT simulation images are not intrepreted by diagnostic radiologists. At the Henry Ford Health System site in West Bloomfield, however, CT treatment planning images are prospectively interpreted by diagnostic radiologists.
Relatively few studies have addressed the incidence of incidental findings detected on planning CTs among cancer patients receiving radiation. As a quality assurance project, an analysis was undertaken to determine the percentage of cases in which previously undetected radiographic findings were found on review of CT simulation images by diagnostic radiology. Furthermore, the clinical significance of these were explored.
MATERIALS AND METHODS
The initial simulation was performed on a Varian Ximatron C-Series radiotherapy simulator. The patient is placed on a Medtec inclined breast board, with the ipsilateral arm raised over the head and placed in arm supports. Although the patient is in this position, the physician places metal wires on the patients' skin, outlining the breast to be treated plus surrounding margins. A wire is also placed on the lumpectomy scar, so that this area can be seen on all films taken during the simulation. The isocenter of the treatment fields is then established. The technologist centers the field over the medial wire exactly halfway between the superior and inferior wires at 100 cm source-to-surface distance. The physician then uses fluoroscopy to cross the wires by rotating the gantry to an angle (away from the treated breast) to ensure that the wires cross at the isocenter and that approximately 2 cm of lung is represented posterior to the isocenter. The patient is then taken to the radiology department for the noncontrast treatment planning CT scan. A flat table top is added to the existing CT table top. This ensures that the patient is placed in a position that replicates that which was in the simulator. The Medtec breast board is then placed on the portable flat table top, and the patient is realigned and rewired for the CT scan as was done in the simulator. Beekley CT spots are placed on all tattoos and the patient is then scanned from 20 cm above to 20 cm below the treatment isocenter, using 5-mm CT slices. Anatomic structures included in the scanned volume include the entire lung, entire heart, partial kidneys, and partial liver. Once the scan is complete, the patient is removed from the table and released to leave. The dosimetrist then imports the CT images into the treatment planning computer and places radiation beams on the CT images. These beams are placed relative to the isocenters from the initial simulation and the planning proceeds. At the Henry Ford Health System West Bloomfield site, CT scan images obtained at the time of simulation are prospectively interpreted by diagnostic radiologists and a formal report is generated. CT simulation scan reports of 332 consecutive breast cancer patients from 2000 to 2006 were retrospectively reviewed and analyzed. The percentage of these reports in which a previously undetected abnormality was noted on the planning CT was determined. Earlier and subsequent diagnostic CT scans were also reviewed to determine the clinical relevance of these diagnostic abnormalities. The study was approved by the Henry Ford Health System Institutional Review Board.
Logistic regression was performed to study the association of undetected abnormalities with patient's age (Ͻ60 or over), smoking history, and cancer stage. The analysis started by first testing for the univariate effect, followed by multivariate modeling. Variable or variable with P Ͻ 0.05 remained in the final model with the estimation of the odds ratio and its confidence limits.
RESULTS
All 332 patients with CT simulations for breast cancer treatment planning were women with a mean age of 60 and a median age of 58. Patients were followed for a median of 26 months. Twenty-six percent of patients had a prior history of smoking. The majority of the patients (48%) had stage I breast cancer.
Fifty-two patients (16%) had some form of a newly detected abnormality noted. Of these, 31 patients (9% of total or 60% of the abnormal findings) were deemed by diagnostic radiology to have potentially significant findings (eg, "cannot exclude metastasic disease") and a follow-up CT or magnetic resonance imaging scan was recommended. There was a statistically significant difference (P Ͻ 0.0001) in the mean age between patients with abnormalities noted on their CT scans versus patients with no abnormalities detected (65.9 vs. 58.5 years, respectively). Furthermore, a significantly higher percentage of patients (P ϭ Ͻ0.01) 60 years of age and older had an abnormality, when compared with those younger than 60 years of age (24% vs. 9%, respectively; Table 1 ). Additionally, the percentage of abnormalities in the smoker and ex-smoker groups (15.9% and 21.4%, respectively) were higher than the percentage of abnormalities in the nonsmoker group (14.6%), although this difference was not statistically significant (P ϭ 0.54; Table 2 ). There was no difference in the distribution of staging between those patients with abnormal findings and those without abnormal findings. There was also no significant difference in percentage of abnormalities detected among the various stages (P ϭ 0.77; Table 2 ). Findings in the 21 patients with visualized abnormalities for which no further workup was indicated included: a renal angiomyolipoma, 3 renal cysts, nonhyperfunctioning adenomas, a parapelvic cyst, several calcifications in the kidney and liver, negligible nodules in the thyroid gland, a lipoma of the lung, calcified pulmonary and splenic granulomas, low-attenuation foci too small to characterize, a fattyreplaced pancreas, 2 cases of bibasilar atelectasis, and 2 small hiatal hernias. Of the 31 patients with potentially significant abnormalities, 14 were found to have previously undetected lung nodules, 7 were diagnosed with liver lesions, 6 were diagnosed with possible kidney or adrenal lesions, 3 were diagnosed with possible sclerosis or diffuse bone lesions, and 1 was diagnosed with a mediastinal mass. In 1 patient, a 4-mm right middle lobe nodule was stable on CT scans obtained at 6 and 11 months after the index study. Radiographic follow-up of a patient with a 5-mm left apex nodule revealed no change at 1 year. Another patient had several less than 5-mm lung opacities, which were unchanged at an 18-month follow-up study. In another patient, an 8-mm lung nodule and several other nodules in its proximity were stable in 6 studies conducted over 36 months. These lesions were felt to most likely be noncalcified granulomas. Continued follow-up, however, was recommended by the interpreting radiologist. In another patient, a 9-mm soft tissue nodule in the right middle lobe was unchanged in appearance and size at nearly 4 years of follow-up. One patient with an oval-shaped nodule in the right middle lobe measuring 15 by 8 mm was assessed by 7 follow-up CT scans over a 4-year period and the lesion remained unchanged (Fig. 1) . Further, no new nodules were detected. A patient with a left adrenal gland mass was found to be stable on 16-month follow-up, favoring a benign adenoma diagnosis. In another patient, whereas a 2-cm ill-defined hypodensity within the medial left hepatic lobe was suspicious for metastatic disease on initial examination, a 40-month follow-up CT of the pelvis indicated no change. Another patient was diagnosed with an anterior-superior mediastinal mass. Follow-up CT thorax scans at 1.5 and 2 years from index study showed an unchanged appearance, and the mass was determined to be a thyroid gland cyst. Finally, a patient with vague pulmonary nodular calcifications and an uncertain density of the left atrium underwent 2 follow-up CT studies at 21 and 28 months. They revealed a stable sized partially calcified left atrial mass with an attachment to the interatrial septum consistent with a calcified atrial myxoma, with no change in size of pulmonary calcified nodules. Follow-up for other patients will continue overtime.
DISCUSSION
This retrospective analysis of CT scans obtained at the time of simulation for radiation treatment planning purposes found that a significant minority (9%) revealed findings that may have clinical relevance and thus required further evaluation. In those patients who underwent follow-up, however, the abnormal findings on CT simulation turned out to be stable to date. As expected our results indicate that advanced age (greater than 60) is associated with an increased incidence of coexistent abnormalities on the planning CT scan. Yet, there was no statistically significant difference in abnormalities based on smoking status.
This study is one of few publications to explore the incidence of unsuspected abnormalities on the radiation planning CT scan among cancer patients. A prior study found that 11% of radiation planning studies among breast cancer patients contained some form of abnormality, with 3% (4 patients) demonstrating unanticipated sites of cancer involvement. 4 In that study, planning studies were reviewed by a radiation oncology resident and attending physician before treatment, but not by a diagnostic radiologist. Findings impacted the overall radiotherapy plan for 3 patients (2%) and resulted in immediate surgical intervention in 1 patient and the delay of the radiotherapy in another patient. The authors concluded that careful review of CT simulation studies by the radiation oncologist is important, and consultations with diagnostic radiologists should be obtained if necessary. 4 Smitt and Mehta examined the incidence of diagnostic radiologist's serendipitous findings in CT planning scans. They found that 20% of patients had incidental benign findings and potential cancer related findings were recorded in 12% of cases. Follow-up and review, however, resulted in few important medical findings and resulted in treatment modification in less than 1% of patients. 5 A retrospective audit of planning CTs for prostate cancer in a group of patients in the United Kingdom revealed 4% of patients were denied definitive radiation treatment on the basis of scan findings. 6 Another study retrospectively reviewed 133 patients who underwent CT simulation before receiving radiotherapy for prostate carcinoma and found that although 6% of patients had "clinically important" coexistent disease, the findings did not require any intervention and did not alter the radiation treatment plan. 7 Furthermore, a prior study found that CT is not cost-effective in detecting unrelated comorbid disease among patients with prostatic carcinoma. 8 CT planning simulations for breast cancer are typically performed without contrast-enhancement and other parameters, such as slice thickness, differ from diagnostic CT studies. Furthermore, patient positioning is typically different from dedicated diagnostic CTs. Finally, radiotherapy CT planning studies are obtained with markers and/or immobilization devices that can create artifacts. These factors may lead to difficulty on the part of diagnostic radiologists to accurately differentiate between a clinically important versus insignificant finding. Although 9% of our patients had potentially significant findings as originally described by diagnostic radiology to date, no clinically relevant findings have been found in this study. This is similar to the results of prior publications in which few of these findings turned out to be clinically relevant. 4, 5, 6, 7 As further follow-up studies of patients with potential abnormalities on planning CTs are conducted, the true impact of these serendipitous findings will be further elucidated.
In this study, a significant proportion of breast cancer patients undergoing CT planning studies were diagnosed with potential abnormalities for which follow-up was recommended by diagnostic radiology. To date, these findings have not been clinically relevant, although further follow-up is needed in many of the patients. Thus, in cases of clinical uncertainty, a diagnostic radiologist may be consulted and follow-up imaging obtained if necessary. This study was focused on breast cancer patients, thus its relevance to other disease sites requires further study.
